Late-Stage COVID-19 Vaccine Candidate Reports Adverse Event

Australia's Deputy Chief Medical Officer Nick Coatsworth confirmed on September 9, 2020, reports AstraZeneca's COVID-19 vaccine candidate AZD1222 had identified a setback in its phase 3 clinical trials. 1News.info reported Dr. Coatsworth stated the company is "working to expedite the review of the .... single event to minimize any potential impact on the trial timeline.

And confirmed the "Australian government is investing in multiple technologies, multiple candidates for a COVID-19 vaccine. We know not all of them will go to market."

A statement from AstraZeneca indicated this type of review is the company's 'standard clinical trial review process', reported local media.